Abstract: The present invention relates to the treatment of disorders using heme oxygenase-1 and heme degradation products.

Abstract: The present invention relates to the treatment of disorders using heme oxygenase-1 and heme degradation products.

Abstract: For the production of hydrocarbons, in particular C2-C4 olefins, using a combined plant with a steam cracker and at least one reactor for converting an educt mixture which includes steam and at least one oxygenate, the respective intermediate product streams of the steam cracker and of the reactor are at least partly combined. To increase the yield of valuable products, a shape-selective zeolite material is used as catalyst in the reactor for oxygenate conversion and at least a part of the product streams obtained downstream of the combined plant is recirculated to the steam cracker and/or the reactor.

Abstract: The present invention relates to a method of treating patients suffering from, or at risk for, intimal hyperplasia and/or arteriosclerosis. The treatment includes administering a pharmaceutical composition that includes carbon monoxide to the patient.

Abstract: The present invention relates to the treatment of disorders using nitric oxide (NO), heme oxygenase-1 (HO-1) and heme degradation products such as carbon monoxide (CO), biliverdin, bilirubin and iron.

Abstract: The present invention relates to a method of treating patients suffering from, or at risk for, intimal hyperplasia and/or arteriosclerosis. The treatment includes administering a pharmaceutical composition that includes carbon monoxide to the patient.

Abstract: The present invention relates to a method of treating patients suffering from, or at risk for, intimal hyperplasia and/or arteriosclerosis. The treatment includes administering a pharmaceutical composition that includes carbon monoxide to the patient.

Abstract: The present invention features methods for transplanting organs, tissues and individual cells. Also featured are methods for maintaining cells in vitro and for enhancing survival and/or function of cells following transplantation. The methods include the administration of carbon monoxide in an amount sufficient to enhance cell survival and/or function.

Abstract: A method to render endothelial cells capable of inhibiting platelet and leukocyte-mediated injury and inflammation is described, comprising genetically modifying the cells by inserting DNA encoding ecto-ATP diphosphohydrolase or an oxidation-resistant analog thereof, and expressing a protein having functional ecto-ATP diphosphohydrolase activity, such as the human CD39 protein, by said cells under cellular activating conditions. The method, which can be carried out in vivo, ex vivo or in vitro, has use in allogeneic or xenogeneic transplantation as well as to treat systemic or local inflammatory conditions characterized by platelet aggregation leading to thrombus formation.

Abstract: The present invention relates to the treatment of disorders using nitric oxide (NO), heme oxygenase-1 (HO-1) and heme degradation products such as carbon monoxide (CO), biliverdin, bilirubin and iron.

Abstract: The present invention relates to a method of treating patients suffering from, or at risk for, intimal hyperplasia and/or arteriosclerosis. The treatment includes administering a pharmaceutical composition that includes carbon monoxide to the patient.

Abstract: The present invention relates to two ATP diphosphohydrolases (ATPDase enzymes) isolated from bovine aorta and pig pancreas, which enzymes have a molecular weight for their catalytic unit of about 78 and 54 Kilodaltons, respectively. A first process for obtaining a highly purified ATPDase is also an object of the present invention. This process has been successfully applied to the purification of both the pancreatic and the aorta enzymes and is deemed to work in the purification of any ATPDase. For both sources of enzymes, the process allows the specific activity of the enzyme to be increased by at least 10,000 fold when compared to the activity retrieved in the crude cell homogenates. The novel process involves an ion exchange chromatography step, a separation on an affinity column, followed by an electrophoresis under non-denaturing conditions.

Abstract: The present invention features methods for transplanting organs, tissues and individual cells. Also featured are methods for maintaining cells in vitro and for enhancing survival and/or function of cells following transplantation. The methods include the administration of carbon monoxide in an amount sufficient to enhance cell survival and/or function.

Abstract: Proteins expressed in NK and some T cells and being transmembrane molecules with Type II membrane protein structure, the extracellular part of the receptor being characterized by a C-type animal lectin domain, DNA sequences encoding such proteins and antibodies against the extracellular part of the transmembrane protein which can activate NK and T cells.

Abstract: The present invention provides a method for enhancing the immunotherapeutic activity, e.g., cytotoxicity, of immune cells by depleting immune cells of a cell subset that down-regulates the immune response, such as either CD4.sup.+ or CD8.sup.+ lymphocytes. The remaining depleted immune cells are then cultured in the presence of interleukin-2 (IL-2) and an antibody to a lymphocyte surface receptor, preferably an anti-CD3 monoclonal antibody (MoAb). The present invention also provides a method of enhancing the immunotherapeutic activity, e.g., cytotoxicity, of immune cells by culturing immune cells in the presence of IL-2 and an antibody to a lymphocyte surface receptor, preferably an anti-CD3 MoAb; separating a cell subset capable of developing immunotherapeutic activity, e.g., cytotoxicity, from the cultured immune cells, e.g., either CD4.sup.+ or CD8.sup.+ lymphocytes; and then subculturing the separated lymphocytes in the presence of IL-2.

Abstract: In accordance with the present invention, a method of culturing lymphocytes is disclosed in which the lymphocytes are cultured in the presence of interleukin-2 (IL-2) and an antibody to a lymphocyte surface receptor, preferably an antibody to a lymphocyte T3 surface receptor. Preferably, the antibody is monoclonal. Cells cultured with anti-CD3 maintain their LAK activity as they increase in number. The cells can also be cultured in the presence of an additional lymphokine to obtain additional LAK activity.Methods of medical treatment are also disclosed in which cells cultured in accordance with the culturing methods of the present invention are introduced into the individual to be treated.

Abstract: Shaped articles with a coherent matrix which comprises homogeneously arranged inorganic solid particles (A) of a size of from about 50 .ANG. to about 0.5 micron, such as silica dust particles, and densely packed solid particles (B) having a size of the order of 0.5-100 micron and being at least one order of magnitude larger than the respective particles A, such as Portland cement particles, the particles A being homogeneously distributed, especially densely packed, in the void volume between the particles B, are made from an easily flowable composite material containing a very low amount of liquid and an extremely high amount of a dispersing agent, such as a concrete superplasticiser.

Abstract: A compact reinforced composite comprising a matrix (A) with a reinforcement (B) embedded therein, the matrix (A) being a composite structure comprising a base matrix (C) which is reinforced with reinforcing bodies (D) in the form of fibers. The transverse dimension of (B) being at least 5 times as large as the transverse dimension of (D).

Abstract: Densified systems and articles made therefrom which contain a composite material comprising a coherent matrix of homogeneously arranged inorganic particles (A) of a size of from about 50 .ANG. to about 0.5 3/4, such as silica dust, and densely packed particles (B) having a size of from 0.5-100 .mu. such as Portland Cement and which are at least one order of magnitude larger than the particles A, and embedded in the matrix, solid particles C made from material having a strength exceeding that of ordinary sand and stone used for ordinary concrete, such as refractory grade bauxite and a surface active dispersing agent. Particles A are homogeneously distributed and especially densely packed, in the void volume between the particles B and are made from an easily flowable composite material containing a very low amount of liquid such as water and an extremely high amount of a dispersing agent such as a concrete superplastisizer.

Abstract: The invention relates to a stable aqueous self-stripping floor cleaning, coating and polishing composition containing a low molecular weight alkali-soluble acrylic type addition-polymer, a fugitive plasticizer, tributoxyethyl phosphate, tetrasodium ethylenediaminetetraacetate, an anionic or nonionic fluorocarbon surfactant, a dimethylpolysiloxane antifoaming agent, 1,2-benzothiazolin-3-one, an alkali metal bicarbonate, water and ammonia to pH 9 to 9.7; and optionally formaldehyde, caprolactam and a styrene-maleic anhydride copolymer, the composition having a solids content of from 5 to 15% by weight.